Genetic variants associated with cisplatin-induced ototoxicity

被引：22
|
作者：
Oldenburg, Jan [1 ,2 ]
Fossa, Sophie D. [1 ,2 ]
Ikdahl, Tone [3 ]
机构：
[1] Univ Oslo, Rikshosp, Norwegian Radium Hosp, Dept Clin Canc Res, N-0310 Oslo, Norway
[2] Univ Oslo, Norwegian Radium Hosp, Fac Div, N-0316 Oslo, Norway
[3] Ullevaal Univ Hosp, Ulleval Canc Ctr, Oslo, Norway
来源：
PHARMACOGENOMICS | 2008年 / 9卷 / 10期
关键词：
audiometric; chemotherapy; cisplatin; glutathione; GST; GSTM1; GSTP1; hearing impairment; hearing loss; ototoxicity; pharmacogenetics; polymorphism; tinnitus;
D O I：
10.2217/14622416.9.10.1521
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Cisplatin induces ototoxicity with a huge interindividual variation, which is at least partly based on genetic differences between the affected individuals. Identification of genetic variants that could predict the severity of ototoxicity is an important step towards a more individualized cisplatin treatment. Nevertheless, so far, only a few studies have assessed this issue. This review will address the prevalence of cisplatin-induced ototoxicity, its pathophysiology, quantification and associations with genetic variants. The recent progress in both phenotyping and genotyping is discussed.
引用
收藏
页码：1521 / 1530
页数：10
相关论文
共 50 条
  • [1] Genetic variation in Otos is associated with cisplatin-induced ototoxicity
    Spracklen, Timothy F.
    Whitehorn, Heather
    Vorster, Anna Alvera
    Ramma, Lebogang
    Dalvie, Sameera
    Ramesar, Rajkumar S.
    PHARMACOGENOMICS, 2014, 15 (13) : 1667 - 1676
  • [2] Genetic variants associated with cisplatin-induced hearing loss
    Pussegoda, K. A.
    CLINICAL GENETICS, 2010, 78 (01) : 33 - U2
  • [3] Economic impact of a genetic test for cisplatin-induced ototoxicity
    Dionne, F.
    Mitton, C.
    Rassekh, R.
    Brooks, B.
    Ross, C.
    Hayden, M.
    Carleton, B.
    PHARMACOGENOMICS JOURNAL, 2012, 12 (03): : 205 - 213
  • [4] Economic impact of a genetic test for cisplatin-induced ototoxicity
    F Dionne
    C Mitton
    R Rassekh
    B Brooks
    C Ross
    M Hayden
    B Carleton
    The Pharmacogenomics Journal, 2012, 12 : 205 - 213
  • [5] Pharmacogenomics of cisplatin-induced ototoxicity
    Mukherjea, Debashree
    Rybak, Leonard P.
    PHARMACOGENOMICS, 2011, 12 (07) : 1039 - 1050
  • [6] Monitoring cisplatin-induced ototoxicity
    Sanchez-Martinez, Ana
    Ignacio Benito-Orejas, Jose
    Jose Tavarez-Rodriguez, Juan
    Lourdes Hernandez-Santos, Maria
    Morais-Perez, Dario
    Soto-Prado, Diego
    REVISTA ORL, 2018, 9 (01): : 25 - 33
  • [7] Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity
    Carleton, B. C.
    Ross, C. J.
    Bhavsar, A. P.
    Amstutz, U.
    Pussegoda, K.
    Visscher, H.
    Lee, J. W.
    Brooks, B.
    Rassekh, S. R.
    Dube, M-P
    Hayden, M. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (03) : 253 - 253
  • [8] Erratum: Economic impact of a genetic test for cisplatin-induced ototoxicity
    F Dionne
    C Mitton
    R Rassekh
    B Brooks
    C Ross
    M Hayden
    B Carleton
    The Pharmacogenomics Journal, 2012, 12 : 359 - 359
  • [9] TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity
    Thiesen, Signe
    Yin, Peng
    Jorgensen, Andrea L.
    Zhang, Jieying E.
    Manzo, Valentina
    McEvoy, Laurence
    Barton, Christopher
    Picton, Susan
    Bailey, Simon
    Brock, Penelope
    Vyas, Harish
    Walker, David
    Makin, Guy
    Bandi, Srinivas
    Pizer, Barry
    Hawcutt, Daniel B.
    Pirmohamed, Munir
    PHARMACOGENETICS AND GENOMICS, 2017, 27 (06): : 213 - 222
  • [10] Systematic review of genetic factors associated with cisplatin-induced ototoxicity reveals TPMT and ACYP2 genetic variants as consistent pharmacogenetic predictors
    Scott, Erika N.
    Joseph, Akshaya A.
    Tanoshima, Reo
    Brooks, Beth
    Rassekh, S. Rod
    Ross, Colin J. D.
    Carleton, Bruce C.
    Loucks, Catrina M.
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2023, 123
12345